There is a category error embedded in most comparisons of MedPricer and Turquoise Health — the implicit assumption that both platforms are trying to answer the same question for the same buyer. They are not. The question Turquoise Health answers, at its core, is: what is everyone else paying? The question MedPricer answers is: what does your specific claims experience imply about optimal contract structure? These are related but distinct problems, and conflating them leads payers to misallocate their analytics investment.
External Benchmarks vs. Internal Optimization
The information architecture of each platform reflects its underlying theory. Turquoise Health is essentially an external benchmarking engine — its value derives from the breadth and currency of its rate index, which allows any given payer to compare its negotiated rates against a market reference. The reference is external to the payer’s own claims experience, which means it is informative about market norms but agnostic about whether those norms are appropriate for the payer’s specific population and utilization patterns. A payer serving a high-acuity, complex patient population may legitimately pay rates above market norms because its patients generate more resource-intensive encounters at the same facility. The benchmark captures this imperfectly.
MedPricer works from the inside out. It ingests a payer’s actual claims data — the encountered services, the payment methodologies applied, the relationship between billed charges and allowed amounts, the distribution of services across billing codes — and models the financial implications of alternative contract structures. The intelligence is specific to the payer’s own actuarial reality rather than to a market aggregate. The limitation is complementary: it optimizes within the existing contract relationship but may not reveal when that relationship is itself extractive relative to market.
The Due Diligence Use Case
One use case where the distinction becomes particularly sharp is pre-merger or pre-acquisition due diligence in the health plan space. An insurer evaluating the acquisition of a smaller regional plan wants to know both what the target is paying for hospital services and whether those rates are defensible in the target market. Turquoise Health’s benchmarking data answers the second question. MedPricer’s contract analytics — applied to the target’s claims — answers the first. Neither tool alone is sufficient for comprehensive due diligence. The private equity firms and strategic acquirers that have been most active in the regional health plan consolidation wave of the past several years have largely learned this through experience, which has driven demand for combined analytical capabilities.
The employer market is learning the same lesson more slowly. The KFF 2023 Employer Health Benefits Survey found that large self-insured employers have increased their investment in benefits analytics substantially, but the analytics are often siloed — one vendor for benchmarking, another for contract modeling, and limited integration between the two. The employer that uses Turquoise Health to discover it is overpaying relative to market but lacks the contract modeling capacity to propose an alternative payment structure has acquired a grievance without a remedy.
The Data Feedback Loop
There is a more subtle dynamic worth considering. As both platforms mature and their datasets grow, the nature of the intelligence they produce will shift. Turquoise Health’s rate index, as it captures more contract cycles and more geographies, begins to reveal not just current rates but the trajectory of rate changes — which markets are seeing rate escalation, which are stable, which are compressing. That longitudinal dimension adds a predictive layer that pure cross-sectional benchmarking lacks. MedPricer’s claims analytics, similarly, becomes more powerful as it accumulates data across clients and can identify pattern deviations — a payer whose contract structure is producing systematically different outcomes than structurally similar clients — that would be invisible from any single client’s perspective. The platforms are not static; they are intelligence infrastructure in ongoing development, and their relative advantages will shift as the underlying data assets mature.
What the market has not yet produced is a seamless integration of these two intelligence streams. The payer that can simultaneously benchmark rates against market norms, model the actuarial implications of alternative contract structures, and track the trajectory of market rate changes in real time is significantly better positioned in contract negotiations than one operating with any single tool. That integrated capability is the white space both platforms have reason to pursue, and the competitive dynamic between them may ultimately be less about market share in existing categories than about who gets there first.
